文献速递肿瘤 PET/CT甲状腺核医学

原发性乳腺癌18F-FES PET/CT与专用乳腺PET显示的瘤内异质性预示化疗反应不均一

Intratumoral Heterogeneity of Primary Breast Cancer on 18 F-FES PET/CT and dbPET Anticipated a Heterogeneous Response to Chemotherapy.
PubMed 文献 · Clin Nucl Med · 2025-01-20

一例59岁cT3N3M1浸润性乳腺癌(ER低阳性、PgR阳性、HER2阴性)患者,于治疗前行18F-FDG与18F-氟雌二醇(18F-FES)PET/CT及专用乳腺PET检查。原发肿瘤大部分区域FES摄取低,但亦见FES高摄取区;紫杉醇联合贝伐珠单抗化疗后18F-FDG PET/CT显示反应良好,但治疗前FES高摄取区见残留病灶。本例提示18F-FES PET可显示原发肿瘤瘤内异质性,且该异质性与后续化疗反应不均一密切相关。

要点

  • 18F-FES PET可显示原发乳腺癌瘤内FES摄取的异质性。
  • 治疗前FES高摄取区在化疗后出现残留病灶。
  • 18F-FDG PET/CT显示整体反应良好,但未反映FES高摄取区的残留。

核心结论

  • 本例提示18F-FES PET可显示原发肿瘤瘤内异质性,且该异质性与后续化疗反应不均一密切相关。

研究设计与样本

  • 个案报道:一例59岁cT3N3M1浸润性乳腺癌(ER低阳性、PgR阳性、HER2阴性)患者。
  • 患者行18F-FDG与18F-FES PET/CT及专用乳腺PET扫描,化疗后行18F-FDG PET/CT。

主要发现

  • 原发肿瘤大部分区域FES摄取低,但亦识别出FES高摄取区。
  • 紫杉醇联合贝伐珠单抗化疗后,18F-FDG PET/CT显示反应良好,但治疗前FES高摄取区见残留病灶。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 59-year-old woman with cT3N3M1 invasive breast cancer (ER low positive, PgR positive, HER2 negative) underwent PET/CT and dedicated breast PET scans using 18 F-FDG and 18 F-fluoroestradiol ( 18 F-FES). While most primary tumor regions displayed low FES uptake, regions of high FES uptake were also identified. Following chemotherapy with the paclitaxel and bevacizumab, 18 F-FDG PET/CT demonstrated a favorable response, but residual disease was noted in areas with high FES uptake on the pretreatment images. This case illustrated that 18 F-FES PET can depict intratumoral heterogeneity within the primary tumor, which was strongly associated with a heterogeneous response to subsequent chemotherapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kitano Y, Miyake KK, Shimizu Y, et al. Intratumoral Heterogeneity of Primary Breast Cancer on 18 F-FES PET/CT and dbPET Anticipated a Heterogeneous Response to Chemotherapy. Clin Nucl Med. 2025. PMID: 39848225. doi:10.1097/RLU.0000000000005660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。